An observational study in Lymphedema, Inflammatory Breast Cancer (IBC) and Preoperative, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 168 studies in Lymphedema with a site in United States — 37 open to participants now, 45 under way, 1 of them phase 3. Lymphedema · United States.
Among the 168 studies in Lymphedema with a site in United States, this one is the 22nd largest by planned enrollment of the 44 observational ones that give a count, is one of 7 that started in 2026, is one of 44 observational ones, reaches primary completion later than 28 of the 44 other live ones, and was the 168th registered.
529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.
Browse Lymphedema studies →37 of the 168 studies in Lymphedema with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 18+
Tactile Medical · Sites in United States
Ages 18+
University Hospital, Basel, Switzerland · Sites in United States, Austria, Canada and 8 more countries
Ages 18+
University of South Florida · Sites in United States
Ages 18–75 · Women only
MMI (Medical Microinstruments, Inc.) · Sites in United States
Ages 22+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 22 · Phase 3 4 · Phase 4 4
First in 2001; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 103 across 145 observational studies indexed under Lymphedema.
Median enrollment 50 across the 122 interventional studies, 148 across the 44 observational. Of the 114 that completed or were terminated, 39 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 168 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 8 studies filed under Lymphedema — fewer than ten, so there is no comparison to draw.
12 of the studies in Lymphedema with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05825157Stanford UniversityEvaluation of Combination Therapy for Upper Extremity Lymphedema | 2027-01-01 |
| NCT02743858Memorial Sloan Kettering Cancer CenterLymphedema Surveillance Study | 2027-04 |
| NCT07012642Advanced Reconstructive Surgery AllianceEfficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema | 2027-04-09 |
| NCT05366699Stanford UniversityLYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy | 2027-06-01 |
| NCT05182229Abramson Cancer Center at Penn MedicineComparing Two Ways to Manage Head and Neck Lymphedema | 2027-06-30 |
Add all 12 to your calendar (.ics) → With an account.
Among the 168 studies in Lymphedema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To find out whether the BIA test can help identify participants with IBC who are at risk for developing lymphedema.
Primary Objectives The primary objective is to reliably describe risk factors for development of BCRL in IBC using BIA.
UT MD Anderson Cancer Center
Eligibility Criteria All women≥18 years old with newly diagnosed inflammatory breast cancer without prior breast/axillary surgery who are eligible for standard of care (NST, MRM, and radiation therapy).
Exclusion Criteria Prior breast/axillary surgery. Participants with pacemakers or other implanted electronic medical devices. Participants with implanted metallic material. All vulnerable populations, including children, pregnant women, and cognitively impaired adult
all patients will start/continue neoadjuvant systemic therapy
Lymphedema Life Impact Scale (LLIS) questionnaire
Time frame: Through study completion; an average of 1 year.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.
Of 56 non-industry observational studies under Lymphedema, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 108. This study's planned 15 months is below that.
Counting every sponsor, half of 59 studies reached it within 45 months; a quarter within 12 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.